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Amy L Strong1, Jeffrey M Gimble1,4, Aline M Betancourt1, Deborah E Sullivan1,5 and Bruce A Bunnell1,2,6*

Abstract
Introduction: Adipose-derived stem cells (ASCs) have emerged as important regulators of inflammatory/immune
responses in vitro and in vivo and represent attractive candidates for cell-based therapies for diseases that involve
excessive inflammation. Acute lung injury (ALI) is an inflammatory condition for which treatment is mainly
supportive due to lack of effective therapies. In this study, the therapeutic effects of ASC-based therapy were
assessed in vivo by comparison of the anti-inflammatory properties of both human and murine ASCs in a mouse
model of lipopolysaccharide (LPS)-induced ALI.
Methods: Human ASCs (hASCs) or mouse ASCs (mASCs) were delivered to C57Bl/6 mice (7.5 × 105 total cells/
mouse) by oropharyngeal aspiration (OA) four hours after the animals were challenged with lipopolysaccharide (15
mg/kg). Mice were sacrificed 24 and 72 hours after LPS exposure, and lung histology examined for evaluation of
inflammation and injury. Bronchoalveolar lavage fluid (BALF) was analyzed to determine total and differential cell
counts, total protein and albumin concentrations, and myeloperoxidase (MPO) activity. Cytokine expression in the
injured lungs was measured at the steady-state mRNA levels and protein levels for assessment of the degree of
lung inflammation.
Results: Both human and mouse ASC treatments provided protective anti-inflammatory responses. There were
decreased levels of leukocyte (for example neutrophil) migration into the alveoli, total protein and albumin
concentrations in BALF, and MPO activity after the induction of ALI following both therapies. Additionally, cell
therapy with both cell types effectively suppressed the expression of proinflammatory cytokines and increased the
anti-inflammatory cytokine interleukin 10 (IL-10). Overall, the syngeneic mASC therapy had a more potent
therapeutic effect than the xenogeneic hASC therapy in this model.
Conclusions: Treatment with hASCs or mASCs significantly attenuated LPS-induced acute lung injury in mice.
These results suggest a potential benefit for using an ASC-based therapy to treat clinical ALI and may possibly
prevent the development of acute respiratory distress syndrome (ARDS).
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Introduction
Acute lung injury (ALI) is a common clinical occurrence
that results from a number of localized and systemic
pathological conditions including sepsis, trauma, shock,
pneumonia, gastric aspiration, toxic ingestion, and pancreatitis. ALI can progress into a life-threatening condition
known as acute respiratory distress syndrome (ARDS) particularly in critically ill patients. ALI/ARDS is characterized by acute onset of overwhelming pulmonary
inflammation, bilateral infiltrates, and diffuse alveolar
damage. Inflammation may progress to the point of widespread pulmonary edema and poor lung compliance that
ultimately result in severe hypoxemia and devastating
respiratory failure [1-3]. Studies indicate that the ageadjusted incidence of ALI/ARDS in the United States is
86.2 per 100,000 person-years, and the mortality rate is 36
to 44% due to lack of an effective therapy [4,5]. Current
treatment for ALI/ARDS is mainly limited to supportive
care including mechanical ventilation with concomitant
treatment of underlying diseases or initiating factors [2].
Given the severe complications and high mortality rate of
ALI/ARDS, a novel and more effective therapy is needed.
Multipotent stromal cells (or mesenchymal stem cells,
MSCs) are a heterogeneous subset of progenitor cells
that have self-renewal and multilineage differentiation
capabilities [6-8]. In recent years, bone marrow-derived
MSCs (BMSCs) have emerged as promising cell-based
therapeutic agents for various inflammatory diseases
given their more recently recognized property of potent
immunomodulation and immunosuppression [8-12].
Encouraging results have been obtained using BMSC
therapy in both rodent and human tissue models of
ALI/ARDS [13-15]. Gupta et al. reported that intrabronchial delivery of murine BMSCs improved survival and
attenuated lipopolysaccharide (LPS)-induced ALI in
mice. This study showed that bronchoalveolar lavage
fluid (BALF) and plasma from endotoxin-challenged
mice treated with BMSCs had lower concentrations of
tumor necrosis factor alpha (TNF-a) and macrophage
inflammatory protein 2 (MIP-2) and higher concentrations of interleukin 10 (IL-10) compared with untreated
mice [13]. Recently, our group reported that, in a mouse
model of LPS-induced acute lung injury, administration
of human BMSCs by oropharyngeal aspiration (OA) significantly reduced the expression of proinflammatory
cytokines, neutrophil counts, total BALF protein and
pulmonary edema. Our study demonstrated that xenogeneic BMSCs recapitulated the observed immunomodulatory effects of syngeneic BMSCs [14]. However, a
critical hindrance in clinical translation of BMSCs is
that bone marrow has a high degree of viral exposure
[16,17], and it may not be practical to obtain BMSCs
from some morbid donors [18,19].
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In contrast, adipose tissue is abundant, expendable,
and easily accessible, and adipose-derived MSCs (that is
adipose-derived stem cells (ASCs) or adipose stem cells)
can be isolated from adipose tissue using a simple protocol that results in high yields, due in part to the
higher frequency of mesenchymal stem cells in the adipose tissue compared to bone marrow. Because they are
easy to acquire and exhibit some of the same immunosuppressive and immunomodulatory characteristics as
BMSCs [20], ASCs are an attractive alternative source of
readily available adult stem cells. However, very little is
known regarding the effect of adipose-derived stem cells
in experimental models of ALI/ARDS. The current
study tests the ability of ASCs isolated from either syngeneic mice or humans to ameliorate lung injury and
suppress inflammation after administration of LPS via
an OA route. This may be the first report describing the
therapeutic role of mouse syngeneic ASC or human
xenogeneic ASC in attenuating ALI in a murine model
of LPS-induced ALI.

Materials and methods
Preparations of human and mouse ASCs

Human and mouse ASCs were isolated and characterized using standard procedures developed at the Pennington Biomedical Research Center [21-23]. All
protocols were reviewed and approved by the Pennington Biomedical Research Center Institutional Review
Board and all human participants provided written
informed consent (PBRC number 23040). The mASCs
were isolated from inbred transgenic C57Bl/6-Tg(UBCGFP)30Scha/J mice (Jackson Laboratories, Bar Harbor,
ME, USA), which ubiquitously express enhanced green
fluorescent protein (eGFP) in all tissues. The cells were
negative for CD11b, CD31, and CD45, and they were
positive for CD29 and CD106 via flow cytometry analysis (data not shown). The cells were able to generate
colony-forming units-fibroblasts (CFU-Fs, data not
shown) and were able to differentiate along adipogenic
and osteogenic lineages (data not shown). Frozen vials
of 1 × 10 6 human or mouse ASCs (passage 3) were
thawed and plated onto a 145 cm2 culture dish (Nunc,
Rochester, NY, USA) in 20 ml complete culture medium
(CCM) that consisted of DMEM/F-12 (GIBCO, Grand
Island, NY, USA), 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA), and 1% Anti-Anti
(antibiotic-antimycotic, GIBCO). The cells were incubated at 37°C with humidified air containing 5% CO2.
After 18 to 20 hours, the medium was removed and
adherent cells were washed once with 1 × phosphatebuffered saline (PBS, GIBCO), harvested with 0.25%
trypsin/1mM EDTA (GIBCO), and replated at 200 cells/
cm2 in CCM for expansion. Media were changed every
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3 to 4 days until the cells reached approximately 70%
confluence. The culture medium was changed to antibiotic-antimycotic-free CCM one day before the cells
were to be delivered to mice. ASCs were harvested with
0.25% trypsin/1 mM EDTA, washed with PBS, resuspended in Hank’s balanced salt solution (HBSS, GIBCO)
and administered to mice via OA as described below.
HBSS alone was used as a vehicle-only control.
ALI induction and treatment protocols

All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at
Tulane University and conformed to the requirements
of the Animal Welfare Act.
To induce acute lung injury, female C57Bl/6 mice
(National Cancer Institute-Frederick, Frederick, MD,
USA) aged 8 to 10 weeks were first anesthetized by
inhalation of 2% isoflurane (VetOne, Meridian, ID, USA)
vapor mixed with oxygen as previously described
[14,24]. Anesthetized mice were suspended by their cranial incisors, and the tongue was extracted to full extension to prevent the swallowing reflex. LPS from
Escherichia coli 055:B5 (15 mg/kg, Sigma-Aldrich, St.
Louis, MO, USA) or PBS vehicle alone (75 µl each) was
pipetted into the back of the throat, and the nares were
pinched shut to force breathing through its mouth and
liquid aspiration. Four hours after LPS challenge, two
doses of human or mouse ASCs (3.75 × 105, suspended
in 75 µl HBSS) or HBSS vehicle-only control (75 µl
each) were delivered by OA 30 minutes apart, for a total
dose of 7.5 × 105 cells (150 µl total volume) per mouse
for each test group. The animals were sacrificed 24 or
72 hours after LPS exposure by exsanguination under
anesthesia with 80 mg/kg ketamine plus 8 mg/kg xylazine. The lungs were processed for bronchoalveolar
lavage (BAL) collection, RNA or protein isolation, or
histology as described below.
Bronchoalveolar lavage

Immediately after exsanguination, the lungs were cannulated with a 20-gauge intravenous (IV) catheter (Exel
International Medical Products, St. Petersburg, FL, USA)
and gently washed five times with 530 μl (right lung) or
1 ml (whole lung) PBS supplemented with 0.4 mM
EDTA (GIBCO) and protease inhibitor cocktail (Roche,
Indianapolis, IN, USA). The lavage fluid was spun at
1,500 × g for 5 minutes at 4°C to pellet the cells. Cells
from all five lavage collections were pooled for total cell
counting while the supernatant from the first lavage was
stored at-80°C for biochemical analysis. The protein
concentration in the bronchoalveolar lavage fluid was
measured using the micro bicinchoninic acid (BCA)
assay kit (Pierce, Rockford, IL, USA). For differential cell
counts, the cells were spun onto glass slides by cytospin
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(Thermo-Shandon, Wilmington, DE, USA) and stained
with a modified Wright-Giemsa stain (Diff-Quik, Fisher
Scientific, Pittsburgh, PA, USA). The numbers of neutrophils, macrophages, eosinophils, basophils, and lymphocytes, up to a total of 100 cells, were determined in
three random viewing fields per sample.
Hematoxylin and eosin (H&E) staining

Lungs were inflation-fixed with 10% neutral buffered
formalin (Sigma-Aldrich) through the trachea at 25 cm
H 2 O pressure for 20 minutes, excised from the mice,
and placed in fresh 10% neutral buffered formalin at 4°
C. The fixed lungs were then embedded in paraffin, and
6 μm sections were stained with H&E to reveal anatomic details. Whole section images were captured on
an Aperio ScanScope (Aperio Technologies, Vista, CA,
USA) and viewed using Aperio ImageScope (Aperio
Technologies).
Lung homogenization, RNA isolation, and cDNA synthesis

Excised lung tissue was weighed and homogenized using
a Bio-Plex cell lysis kit (Bio-Rad, Hercules, CA, USA) as
per the manufacturer’s instruction. The homogenates
were centrifuged at 10,000 × g for 15 minutes, and the
supernatant was aliquoted and stored at-80°C until analyzed. The protein concentration in the supernatant was
measured by BCA assay. Total RNA was isolated from
lung tissue homogenized in TriPure Isolation Reagent
(Roche) and was purified with the RNeasy mini kit (Qiagen, Valencia, CA, USA). The RNA was first treated
with DNase I (Amplification grade, Invitrogen) and then
converted into cDNA using iScript cDNA Synthesis Kit
(Bio-Rad) following the manufacturer’s instructions in a
PTC-200 Peltier Thermal Cycler (MJ Research, Ramsey,
MN, USA).
Real-time RT-PCR

The persistence of viable hASCs or mASCs in the lung
was determined at 20 hours after the cells were delivered using real-time RT-PCR for human glyceraldehyde3-phosphate dehydrogenase (GAPDH) or eGFP mRNA,
respectively, as previously described [14,25]. TaqMan
Gene Expression Assay (Hs00266705_g1, Applied Biosystems, Foster City, CA, USA) was used to specifically
quantify human GAPDH. The following primer/probe
set was used to quantify eGFP: forward 5’-CCACATGAAGCAGCAGGACTT-3’, reverse 5’-GGTGCGCT
CCTGGACGTA-3’, and probe 5’-6FAM-TTCAAGTC
CGCCATGCCCGAA-TAMRA-3’. Briefly, 7.5 × 10 5
hASCs or mASCs were added to a whole lung tissue
sample just prior to homogenization and RNA isolation.
Standard curves were generated by adding serial dilutions of mRNA isolated from lung tissue plus ASCs to
mRNA isolated only from lung tissue. Real-time RT-
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PCR was performed, and Ct values were used to determine the persistence of hASCs or mASCs according to
the standard curves. The final value for total cDNA in
the sample was corrected by parallel real-time RT-PCR
assays with primers that amplified both the human and
the mouse genes for GAPDH (forward 5’-CAGCGACACCCACTCCTCCACCTT-3’, reverse 5’-CATGA
GGTCCACCACCCTGTTGCT-3’) and mouse ribosomal
protein, large, P0 (Rplp0, forward 5’-CGACCTGGAAGTCCAACTAC-3’, reverse 5’-ATCTGCTGCATCTGCTTG-3’). Results were presented as the
percentage of the calculated cell number relative to the
delivered cell number (7.5 × 105). For cytokine/chemokine expression analysis, the real-time PCR reactions
were performed as previously described by Ripoll et al.
with modifications [9]. Briefly, each reaction mixture
contained 1 µl of commercially available TaqMan GeneExpression Assay primer/probe set (Applied Biosystems), 10 µl TaqMan Gene Expression Master Mix
(Applied Biosystems), 50 ng cDNA template and RNasefree water with a total volume of 20 µl. Beta-actin (bactin) was used as an endogenous control. The reaction
was performed at 50°C for 2 minutes, 95°C for 10 minutes followed by a 40-cycle two-step PCR (95°C for 15
seconds and 60°C for 1 minute) using the CFX96 RealTime System (Bio-Rad). TaqMan GeneExpression
Assays (Applied Biosystems) used for murine genes
were: b-actin (Mm00607939_s1), macrophage inflammatory protein 2 (MIP-2, Mm00436450_m1), interleukin 1 alpha (IL-1a, Mm00439621_m1), IL-1b
(Mm01336189_m1), MIP-1a (Mm00441258_m1), and
tumor necrosis factor alpha (TNF-a, Mm00443258_m1),
and IL-10 (Mm01288386_m1).
Myeloperoxidase activity assay, ELISA, and multiplex
immunoassay

BALF myeloperoxidase (MPO) activity assay was performed as previously described [14]. Briefly, BALF was
added to a reaction buffer containing 50 mM potassium
phosphate (pH 6.0), 0.0005% (v/v) H2O2, and 0.167 mg/ml
o-dianisidine dihydrochloride (Sigma-Aldrich); the absorbance at 460 nm was monitored for 30 minutes using the
Synergy HT multi-detection microplate reader (Bio-Tek
Instruments, Winooski, VT, USA). The albumin levels in
BALF were measured using a mouse albumin ELISA kit
purchased from Bethyl Laboratories (Montgomery, TX,
USA). Measurement of cytokines and chemokines in lung
homogenates was performed by multiplex immunoassay
using a Millipore mouse cytokine/chemokine 32-plex kit
(Millipore, Billerica, MA, USA).
Statistical analysis

Data are summarized as mean ± SEM. One-way
ANOVA was performed for statistical analysis, followed
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by Bonferroni multiple comparison tests. The statistical
significance value was set at P <0.05.

Results
Engraftment of hASCs and mASCs in the lung

Real-time RT-PCR for human GAPDH or eGFP was
performed to track hASCs and mASCs, respectively, in
the lungs 20 hours after being delivered through oropharyngeal aspiration. It was determined that 20.85 ±
3.65% (N = 4) of administered hASCs could be found in
the lungs in the PBS + hASC group, whereas there was
21.38 ± 2.49% (N = 4) in the LPS + hASC group based
on real-time RT-PCR results. For mASCs, 15.18 ± 0.55%
(N = 4) of delivered cells were detected in the PBS +
mASC group, while 19.88 ± 1.83% (N = 5) in the LPS +
mASC group (Figure 1a).
Change in body weight following treatment

The body weight of each mouse was determined immediately prior to LPS (or PBS control) challenge and
again at the time of sacrifice (24 hours after LPS exposure). The change in body weight was calculated as percentage relative to the basal body weight. While intact,
untreated mice (N = 7) gained about 2% body weight
during this 24-hour period, mice in the PBS + hASC (N
= 6) and PBS + mASC (N = 6) control groups lost 2 to
3% body weight during the 24-hour period. For the diseased mice induced by LPS, the percentage of body
weight lost was reduced following hASC (10.19 ± 0.85%,
N = 10, P >0.05) and mASC (7.14 ± 0.52%, N = 10,
P <0.001) treatment, as compared to the HBSS vehicleonly controls (11.82 ± 0.66%, N = 16) (Figure 1b).
Assessment of lung histology and microvascular
permeability

To determine the effect of hASCs or mASCs treatment
on the lung injury, H&E staining of lung sections from
animals 72 hours after LPS challenge was examined
using an Aperio ScanScope. Both hASCs and mASCs
markedly decreased lung injury after LPS exposure; specifically, both cell types reduced cellularity, exudation
and septal thickening compared to HBSS vehicle-only
controls (Figure 2a-c).
Massive inflammation causes vascular leakage in the
lung in this LPS-induced ALI mouse model [13,14], as
indicated by the elevated levels of protein and albumin
in BALF (Figure 2d, e). To assess the effect of hASCs or
mASCs on the integrity of the alveolar-capillary membrane barrier and pulmonary vascular leakage, the levels
of total protein and albumin in the bronchoalveolar
lavage fluid were examined 24 hours after PBS or LPS
challenge. Results demonstrated that total protein concentration in BALF was reduced in both the hASC (N =
9) and mASC (N = 10) treatment groups compared to
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Figure 1 Persistence of hASCs and mASCs and change in body weight. (a) The percentages of total injected hASCs or mASCs present in
the lung 20 hours after oropharyngeal administration for PBS-and LPS-challenged mice. Real-time RT-PCR analysis using human GADPH and
eGFP primers was used to track and quantify the hASCs and mASCs, respectively. N = 4, 4, 4, and 5 for PBS + hASC, PBS + mASC, LPS + hASC,
and LPS + mASC, respectively. (b) Changes in body weight following treatment with HBSS, hASC, or mASC were compared 24 hours after PBS
or LPS challenge. N = 7, 6, 6, 16, 10, and 10 for Intact, PBS + hASC, PBS + mASC, LPS + HBSS, LPS + hASC, and LPS + mASC, respectively.
Significance was defined as *** for P <0.001, for comparison of the experimental cell treatment groups to the HBSS-treated LPS-challenged mice.
eGFP, enhanced green fluorescent protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; hASCs, human adipose-derived stem cells; HBSS,
Hank’s balanced salt solution; LPS, lipopolysaccharide; mASCs, mouse adipose-derived stem cells; PBS, phosphate-buffered saline; RT-PCR, reverse
transcription-polymerase chain reaction.

the HBSS-only control group (N = 10), however, statistical significance (P <0.001) was reached only in the
mASC treatment group. Administration of hASCs (N =
9) and mASCs (N = 10) resulted in significantly lower
concentrations of BALF albumin, about 41% and about
56% lower than those of HBSS (N = 10) vehicle-treated
mice (P <0.01 and P <0.001, respectively). Interestingly,
these parameters showed a trend that treatment with
mASCs decreased BALF total protein and albumin even
more than hASC treatment, although this effect was not
statistically significant.
Effect of hASCs and mASCs on the infiltration of
inflammatory cells

Inflammatory cell migration and infiltration into the site
of inflammation is extremely important in the tissue
damage of lung injury [26]. To evaluate the effect of
hASCs and mASCs on inflammatory cell infiltration in
the lung after LPS injury, the total cell number in BALF
was counted using a hemocytometer. The BAL total cell
number 24 hours after LPS challenge in the HBSS control group was 2.73 × 106 ± 0.57 × 106 (N = 10), while

this number was significantly decreased due to the
administration of hASCs or mASCs to 1.43 × 106 ± 0.22
× 106 (N = 9, P <0.05) or 1.20 × 106 ± 0.15 × 106 (N =
10, P <0.01), respectively (Figure 3a). A modified
Wright-Giemsa stain was performed to differentiate the
different cell types in BAL. The vast majority of infiltrating cells were neutrophils in all LPS injury groups.
Treatment with hASC and mASC reduced the infiltrating neutrophil number from 2.41 × 106 ± 0.54 × 106 (N
= 10) in the control to 1.24 × 106 ± 0.20 × 106 (N = 9,
P <0.05) and 0.91 × 106 ± 0.12 × 106 (N = 10, P <0.01),
respectively (Figure 3b). MPO activity in BALF 24 hours
after LPS challenge was also analyzed as an alternative
measure of neutrophil infiltration in the tissue under
pathological conditions. In both hASC and mASC treatment groups, MPO activity was significantly decreased
from the high level of 3.21 ± 0.69 mU/min/ml (N = 10)
in control mice to 1.23 ± 0.26 mU/min/ml (N = 9, P
<0.05) and 0.31 ± 0.13 mU/min/ml (N = 10, P <0.01),
respectively (Figure 3c). There were fewer BAL total
cells and neutrophils, as well as lower MPO activity, in
the mASCs group as compared to the hASCs treatment
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Figure 2 hASCs and mASCs improved severity of lung injury. Representative H&E lung sections 72 hours following LPS challenge for mice
treated with (a) HBSS (N = 5), (b) hASCs (N = 5), or (c) mASCs (N = 5). Comparisons at the alveolar level (enlarged images) show decreased
cellularity, septal thickening, and exudation when hASCs or mASCs were administered following LPS challenge. Levels of (d) protein and (e)
albumin in the bronchoalveolar lavage fluid were used to assess the extent of vascular leakage after HBSS or ASC treatment. Control groups with
intact or PBS-challenged mice were included to assess any changes in these levels due to the injection method or cell treatment. Values were
presented as fold changes relative to intact, untreated mice. For (d) and (e), N = 3, 6, 6, 10, 9, and 10 for Intact, PBS + hASC, PBS + mASC, LPS +
HBSS, LPS + hASC, and LPS + mASC, respectively. Significance was defined as ** and *** for P <0.01 and P <0.001, respectively, for comparison
of the experimental cell treatment groups to the HBSS-treated LPS-challenged mice. ASC, adipose-derived stem cell; hASCs, human adiposederived stem cells; HBSS, Hank’s balanced salt solution; H&E, hematoxylin and eosin; LPS, lipopolysaccharide; mASCs, mouse adipose-derived
stem cells; PBS, phosphate-buffered saline.
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Figure 3 Characterization of human and mouse ASC effects on inflammatory cell infiltration in the lung after LPS injury. Administration
of hASCs or mASCs, when compared to HBSS, significantly decreased the (a) total cell number, (b) infiltrating neutrophil number as determined
by a modified Wright-Giemsa stain, and (c) MPO activity in BALF 24 hours after LPS exposure. For (a) and (b), N = 3, 6, 6, 10, 9, and 10 for Intact,
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as compared to the HBSS-treated LPS-challenged mice. ASC, adipose-derived stem cell; BALF, bronchoalveolar lavage fluid; hASCs, human
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myeloperoxidase; PBS, phosphate-buffered saline.
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group; however, these differences were not found to be
statistically significant.
Regulation of cytokine expression by hASCs and mASCs

To determine the regulatory effects of hASC and
mASCs on inflammatory responses in the lung, total
RNA was isolated from the lung tissue and the mRNA
levels of various proinflammatory cytokines and chemokines were assessed by quantitative, real-time RT-PCR.
ß-actin was used as an endogenous control, and the
gene expression level was normalized to the unchallenged and untreated mice to show fold changes. As
expected, the lungs from the PBS-challenged control
mice treated with hASCs (N = 4) or mASCs (N = 4)
had very low levels of the inflammatory markers, while
those challenged with LPS and treated with HBSS (N =
5) increased the expression of proinflammatory cytokines and chemokines dramatically. Treatment with
hASCs (N = 4) and mASCs (N = 5) suppressed the
steady-state mRNA levels of MIP-2 (P <0.01 and P
<0.001, respectively), IL-1a (P <0.001 and P <0.001,
respectively), IL-1b (P <0.05 and P <0.001, respectively),
MIP-1a (P <0.001 and P <0.001, respectively), and TNFa (P >0.05 and P <0.001, respectively), as compared to
the HBSS-only controls (Figure 4a-e) 24 hours after LPS
challenge. Treatment with mASCs suppressed the
expression of IL-1a, MIP-1a, and TNF-a (P <0.01, P
<0.05 and P <0.05, respectively) more so than treatment
with hASCs. For MIP-2 and IL-1b, the data showed a
similar trend, but the difference between mASC and
hASC treatment was not statistically significant. With
mASC treatment, the level of the anti-inflammatory
cytokine IL-10 was slightly increased compared to the
HBSS treatment control (P >0.05); however, this effect
was not noticed in the hASC treatment group.
To further investigate the protein levels of pro-and
anti-inflammatory cytokines/chemokines in the lung in
response to hASCs (N = 4) or mASCs (N = 5) therapy
24 hours after LPS injury, a multiplex immunoassay was
performed on mouse lung homogenates with results
normalized to total protein concentration of each sample. The results showed trends for decreased production
of MIP-2, IL-1b, interferon gamma (IFN-g), and granulocyte macrophage colony-stimulating factor (GM-CSF)
following hASCs and mASCs administration, without
affecting the secretion of IL-1a (Figure 5a-e). The production of the anti-inflammatory cytokine IL-10 was significantly increased in the mASC treatment group (P
<0.01) and only slightly increased in the hASC treatment group as compared to the HBSS control (N = 5).

Discussion
According to the Berlin definition of ARDS, the term
acute lung injury (ALI) has been eliminated since 2011
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[27], however, the majority of the field still uses ALI as
a valid denomination. For the purpose of this article, we
still use the term ALI. Given that excessive inflammatory responses play a crucial role in the pathophysiology
of ALI/ARDS [2], immunomodulatory therapy is an
attractive new approach in the treatment of such afflictions [28,29]. Multipotent stromal cells provide unique
opportunities for developing novel treatments for a large
array of inflammatory diseases, because MSCs possess
potent immunomodulatory properties and are often
considered to be hypoimmunogenic or ‘immunoprivileged’ [10,30]. An emerging body of data indicates that
either human or mouse bone marrow-derived MSCs
(BMSCs) alleviate tissue damage and suppress inflammatory reactions in different models of ALI [13-15,31].
As an alternative source of mesenchymal stem cells, adipose tissue is abundant and easily accessible, and high
yields of adipose-derived MSCs (ASCs) are easier to isolate with less invasive procedures. ASCs have been
reported to have similar immune regulatory capabilities
as BMSCs [20,32]. While the use of BMSCs to treat
ALI/ARDS is promising, there is little known about the
potential therapeutic effects of ASCs in this disease setting. In this study, the therapeutic effect of human-and
mouse-derived ASCs was investigated in a mouse model
of LPS-induced ALI.
Endotoxin (bacterial LPS)-induced ALI in mice is a
widely used experimental model to investigate the
pathogenesis and treatment of ALI/ARDS. However, it
should be noted that no single ALI animal model can
completely reproduce all the pathophysiological features
of ALI/ARDS in humans. The airway LPS administration model employed in these studies results in massive
alveolar neutrophil infiltration, which is also seen in
human ALI/ARDS [33,34].
In this study the relatively noninvasive OA method
[24] was used to administer both LPS and ASCs. A previous study from our group showed a comparable beneficial effect using the IV, intraperitoneal (IP), and OA
methods to deliver human BMSCs to LPS-challenged
mice [14].
Taking advantage of the cross-species nature of hASCs
and the eGFP marker of mASCs in our experiments, the
persistence of the cells in the lungs after delivery
through OA was confirmed by real-time RT-PCR for
human GAPDH and eGFP. It is expected that the cells
detected reflect persistence of live cells since mRNA for
human GAPDH and eGFP was detected as markers for
human and mouse ASCs, respectively.
These results demonstrated that treatment of ALI with
either hASCs or mASCs decreased the body weight loss
following ALI induction, which suggests lower disease
severity following treatment. Both treatments decreased
LPS-induced lung damage and neutrophil infiltration
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Figure 4 Regulatory effects of hASCs and mASCs on inflammatory responses in the lung. The lung mRNA levels of various
proinflammatory cytokines and chemokines 24 hours after PBS or LPS challenge were quantified using real-time RT-PCR. All levels were
normalized to beta-actin and reported as fold changes compared to unchallenged and untreated mouse levels. Steady-state mRNA levels of (a)
macrophage inflammatory protein 2 (MIP-2), (b) interleukin 1 alpha (IL-1a), (c) IL-1b, (d) MIP-1a, (e) tumor necrosis factor alpha (TNF-a), and (f)
IL-10 are shown for PBS-or LPS-challenged mice injected with HBSS, hASCs, or mASCs. N = 2, 4, 4, 5, 4, and 5 for Intact, PBS + hASC, PBS +
mASC, LPS + HBSS, LPS + hASC, and LPS + mASC, respectively. Significance was defined as *, **, and *** for P <0.05, P <0.01, and P <0.001,
respectively, compared to control groups; significant differences between the LPS-challenged cell-treatment groups (LPS + hASC and LPS +
mASC) were denoted by ## for P <0.01. hASCs, human adipose-derived stem cells; HBSS, Hank’s balanced salt solution; LPS, lipopolysaccharide;
mASCs, mouse adipose-derived stem cells; PBS, phosphate-buffered saline; RT-PCR, reverse transcription-polymerase chain reaction.
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Figure 5 The effects of hASC and mASCs on inflammatory cytokine levels in the lung. Protein levels of various proinflammatory cytokines
and chemokines 24 hours after PBS or LPS challenge were quantified for lung lysates using a multiplex immunoassay. All levels were normalized
to total lung lysate protein concentration. Protein levels of (a) macrophage inflammatory protein 2 (MIP-2), (b) interleukin 1 alpha (IL-1a), (c) IL1b, (d) interferon gamma (IFN-g), (e) granulocyte macrophage colony-stimulating factor (GM-CSF), and (f) IL-10 are shown for PBS-or LPSchallenged mice injected with HBSS, hASCs, or mASCs. N = 4, 4, 5, 4, and 5 for PBS + hASC, PBS + mASC, LPS + HBSS, LPS + hASC, and LPS +
mASC, respectively. Significance was defined as ** for P <0.01 compared to HBSS-treated LPS-challenged mice levels. hASCs, human adiposederived stem cells; HBSS, Hank’s balanced salt solution; LPS, lipopolysaccharide; mASCs, mouse adipose-derived stem cells; PBS, phosphatebuffered saline.
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substantially, as shown by H&E staining. This was
further corroborated by decreased levels of total protein
and albumin in BALF, indicating reduced endothelial
and epithelial permeability in the lung following either
hASCs or mASCs treatment.
Because neutrophil activation and transmigration into
lung interstitium and broncheoalveolar space plays a
crucial role in the development of ALI [26], it can be
inferred that decreasing infiltration of neutrophils using
ASCs administration may have clinically relevant therapeutic potential. Activated neutrophils secrete proteinases and potent enzymes such as MPO that generate
oxidants, all of which can damage lung tissue leading to
edema and loss of lung function [35]. Decreased MPO
activity after cell treatment indicates that both hASCs
and mASCs are capable of decreasing the lung inflammatory responses that ultimately cause the neutrophilassociated tissue damage common in ALI.
Nemeth et al. and Anderson et al. showed that mouse
BMSCs and ASCs were able to reprogram macrophages
to increase their IL-10 production, and the administration of these cells protected mice from sepsis [12,32]. In
this study, both hASC and mASC treatments led to a
reduction of the expression of various proinflammatory
cytokines/chemokines, while increasing the production
of the anti-inflammatory cytokine IL-10. These data suggest that the anti-inflammatory effects of hASC and
mASC in this model were mediated, at least in part, by
the increased production of IL-10 in the lung. The
decrease of the production of proinflammatory cytokines/chemokines at the protein level was found to be
not as pronounced as that at the mRNA level 24 hours
after LPS exposure. This may be explained by the time
lag between translation and transcription.
It is important to note that while cytokine and chemokine levels were quantified in the lungs of mASC-treated
mice, the cellular source of the cytokines or chemokines
(that is, lung epithelial cells, alveolar macrophages,
inflammatory cells or administered ASCs) was not able
to be determined. Our previous study showed that,
when stimulated with LPS or BALF, mASCs did secrete
some cytokines and chemokines (for example IL-1a and
MIP-1a) in vitro (data not shown). These data suggest
that decreased cytokine levels in animals treated with
mASCs may actually be lower than recorded since the
mASC may act as an exogenous source of these cytokines. However, the expression of cytokines and chemokines from human ASCs could not be detected since
human cytokines and chemokines would not be detected
by mouse specific primers. Therefore, using human
ASCs offers the possibility of determining how the
ASCs are responding to the injured lung, because
human specific primers or antibodies can be used.
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To the best of our knowledge, this is the first report
to demonstrate the beneficial effects of ASCs for the
treatment of LPS-induced acute lung injury in vivo.
Moreover, the therapeutic effects of human and mouse
ASCs have been compared side by side. While both
hASCs and mASCs significantly attenuated the lung
injury and inflammation, some notable differences
between the two cell types were observed. For most of
the parameters examined, mASCs had a more beneficial
effect than xenogeneic hASCs. A possible explanation
for this observation is that the cross-talk between
mASCs and the injured mouse lung is more effective
than in the xenotransplantation model using hASCs. In
addition, studies have demonstrated species variation in
the mechanisms of bone marrow-derived MSC-mediated
immunosuppression. Ren et al. showed that under the
same culture conditions, immunosuppression by human
or monkey BMSCs was mediated by indoleamine 2,3dioxygenase, while mouse BMSCs utilized nitric oxide
[36]. The species variation may also be an explanation
to the different therapeutic effects of hASCs and mASCs
in this ALI model.
To advance the use of stem cell therapy in the treatment of ALI/ARDS it is essential that the molecular
mechanisms behind any observed beneficial effects be
understood. As discussed above, there is increasing evidence that both mouse and human BMSCs have similar
anti-inflammatory properties, however the mechanisms
mediating these outcomes may be unique to each cell
type. Similarly, our unpublished data suggest that
human and mouse ASCs suppress inflammation in the
lung by different mechanisms. Therefore, it is essential
that human cells be used in preclinical studies employing animal models. However concerns that the protective factors produced by human MSCs may not be
effective in other species have limited such studies.
Results from this study demonstrate potent anti-inflammatory effects of both human and mouse ASCs in wildtype mice exposed to LPS, a well-characterized model of
ALI. While syngeneic mouse ASCs were expectedly
more effective at suppressing inflammation, our results
clearly demonstrate the feasibility of using immunocompetent mice to interrogate the molecular mechanisms by
which human ASCs suppress inflammation.
There are currently more than 60 clinical trials registered with clinicaltrial.gov testing ASCs in a variety of
disorders, including Crohn’s fistula, type 2 diabetes, and
chronic obstructive pulmonary disease. As discussed
above, ASCs are easy to isolate and expand in vitro, and
they are also ‘immunoprivileged’ [37], which makes allogeneic transplantation to humans feasible. Despite the
promising results we obtained in the mouse model, clinicians should use caution when considering the use of
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ASCs as a therapy for ALI/ARDS in human subjects. A
recent study showed that in both humans and mice, intravenous infusion of ASCs did not induce any serious
adverse events related to ASC transplantation or any
tumor development (even in nude mice) [38]. However,
other studies have indicated that ASCs enhance tumorigenesis and metastasis of breast cancer cell lines and primary breast cancer samples [39,40]. Our recently published
data showed that ASCs isolated from the subcutaneous
abdominal adipose tissue of obese subjects have enhanced
invasion toward breast cancer cells [41]. Prantl et al.
demonstrated that ASCs promote prostate tumor growth
[42]. Therefore, before use in human subjects, the safety of
ASCs should be fully investigated and evaluated, particularly in patients with breast cancer and prostate cancer.

Conclusions
This study suggests that the transplantation of human or
mouse ASCs by oropharyngeal aspiration effectively
attenuates lung injury and inflammation in a mouse
model of LPS-induced ALI. These therapeutic effects may
be partially due to the increased production of IL-10 in
the lung following the cell-based treatment. A side-byside comparison indicated that mASCs are more potent
than hASCs in mediating the therapeutic effects following
LPS-induced ALI in this mouse model. Therefore, adipose-derived stem cells may serve as a novel treatment
modality for ALI, a medical challenge that currently lacks
efficient therapies beyond supportive care.
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